We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 19 for:    fibrodysplasia ossificans progressiva

The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) (OPTIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05394116
Recruitment Status : Recruiting
First Posted : May 27, 2022
Last Update Posted : January 18, 2023
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:

The study population consists of patients with Fibrodysplasia ossificans progressiva (FOP).

Key primary objectives are:

  1. To assess the effect of high dose garetosmab versus placebo on the formation of new heterotopic ossification (HO) lesions from baseline to week 56, as determined by low-dose computed tomography (CT)
  2. To assess the safety and tolerability of garetosmab versus placebo from baseline to week 56

Key Secondary Objectives:

  1. To assess the effect of high dose garetosmab versus placebo on the number per participant of clinician-assessed flare-up episodes to week 56
  2. To assess the effect of low dose garetosmab versus placebo on the formation of new HO lesions from baseline to week 56 as determined by CT
  3. To assess the effect of low dose garetosmab versus placebo on the number per patient of clinician-assessed flare-up episodes to week 56

Condition or disease Intervention/treatment Phase
Fibrodysplasia Ossificans Progressiva Drug: Garetosmab Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
Actual Study Start Date : November 21, 2022
Estimated Primary Completion Date : March 5, 2025
Estimated Study Completion Date : March 5, 2026


Arm Intervention/treatment
Experimental: High dose Garetosmab
Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
Drug: Garetosmab
Garetosmab is supplied as a liquid drug product and will be administered IV.
Other Name: R2477

Experimental: Low dose Garetosmab
Garetosmab is administered by IV administration Q4W
Drug: Garetosmab
Garetosmab is supplied as a liquid drug product and will be administered IV.
Other Name: R2477

Experimental: Placebo
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Drug: Placebo
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.




Primary Outcome Measures :
  1. Number of new HO lesions adjudicated as positive based on CT [ Time Frame: Through week 56 ]
  2. Incidence and severity of treatment-emergent adverse events of special interest (AESIs) [ Time Frame: Baseline to Week 56 ]

Secondary Outcome Measures :
  1. Number of clinician-assessed flare-ups [ Time Frame: Through Week 28 and Week 56 ]
    Investigator assess flare-up events according to his/her medical judgment. A FOP flare-up is characterized as episodic, painful inflammatory soft tissue swelling

  2. Occurrence of clinician-assessed flare-ups [ Time Frame: Through Weeks 28 and 56 ]
    Reported as Yes/No

  3. Number of patient-reported flare-ups [ Time Frame: Through Weeks 28 and 56 ]
    Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily.

  4. Occurrence of patient-reported flare-ups [ Time Frame: Through Weeks 28 and 56 ]
    Reported as Yes/No

  5. Occurrence of new HO lesions adjudicated as positive based on CT [ Time Frame: Weeks 28 and 56 ]
    Reported as Yes/No

  6. Total volume of new HO lesions adjudicated as positive based on CT [ Time Frame: Weeks 28 and 56 ]
  7. Number of new HO lesions adjudicated as positive based on CT [ Time Frame: Week 28 ]
  8. Change in joint function assessment by physician using cumulative analog joint involvement scale (CAJIS) [ Time Frame: Baseline to Week 28 and 56 ]
    CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30

  9. Change in pulmonary function as assessed by spirometry [ Time Frame: Baseline to Week 28 and 56 ]
    Forced vital capacity (FVC) and Forced expiratory volume in 1 second (FEV1) and the ratio of FEV1/FVC will be determined by spirometry.

  10. Change in disease severity as assessed by the Patient Global Impression of Severity (PGIS) [ Time Frame: Baseline to Week 28 and 56 ]
    PGIS is a single item, self-administered questionnaire to assess the patient's global impression of severity

  11. Change in disease severity as assessed by the Patient's Global Impression of Change (PGIC) [ Time Frame: Baseline to Week 28 and 56 ]
    PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change

  12. Change in disease severity as assessed by the Clinician's Global Impression of Change (CGIC) [ Time Frame: Baseline to Week 28 and 56 ]
    CGIC is a single-item questionnaire to assess the clinician's global impression of change

  13. Concentration of total activin A in serum over time [ Time Frame: Baseline to Week 56 ]
  14. Concentrations of garetosmab in serum [ Time Frame: Baseline to Week 56 ]
  15. Incidence of anti-drug antibodies (ADA) to garetosmab [ Time Frame: Baseline to Week 56 ]
  16. Titer of ADA to garetosmab [ Time Frame: Baseline to Week 56 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Male or female 18 years or older at screening
  2. Clinical diagnosis of Fibrodysplasia Ossificans Progressiva (FOP) [(based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive Heterotopic Ossification (HO)]
  3. Confirmation of FOP diagnosis with documentation of Type I activin A receptor (ACVR1) FOP causing mutation
  4. FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, or other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of HO lesions (increase in size or number of HO lesions) with/without being associated with flare-up episodes
  5. Willing and able to undergo CT imaging procedures and other procedures as defined in the protocol

Key Exclusion Criteria:

  1. Cumulative Analog Joint Involvement Scale (CAJIS) score at screening >19
  2. Participant has significant concomitant illness or history of significant illness such as but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic, or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study
  3. Previous history or diagnosis of cancer
  4. Severely impaired renal function defined as estimated glomerular filtration rate <30 milliliter per minute (mL/min) (/1.73 m^2 calculated by the Modification of Diet in Renal Disease equation
  5. Uncontrolled diabetes defined as hemoglobin A1C (HbA1c) >9% at screening
  6. History of poorly controlled hypertension, as defined by:

    1. Systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg at the screening visit
    2. Systolic blood pressure of 160 mm Hg to 179 mm Hg or diastolic blood pressure of 100 mm Hg to 109 mm Hg at the screening visit, AND a history of end-organ damage (including history of left-ventricular hypertrophy, heart failure, angina, myocardial infarction, stroke, transient ischemic attack, peripheral arterial disease, end-stage renal disease, and moderate-to-advanced retinopathy
  7. Known history of cerebral vascular malformation
  8. Cardiovascular conditions such as New York Heart Association class III or IV heart failure, cardiomyopathy, intermittent claudication, myocardial infarction, or acute coronary syndrome within 6 months prior to screening; symptomatic ventricular cardiac arrhythmia
  9. History of severe respiratory compromise requiring oxygen, respiratory support (eg, bilevel positive airway pressure [biPAP] or continuous positive airway pressure [CPAP]), or a history of aspiration pneumonia requiring hospitalization
  10. Prior use in the past year and concomitant use of bisphosphonates
  11. Concurrent participation in another interventional clinical study or a non-interventional study with radiographic measures or invasive procedures (eg, collection of blood or tissue samples).
  12. Treatment with another investigational drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer
  13. Pregnant or breastfeeding women
  14. Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception
  15. Male patients with WOCBP partners who are not willing to use condoms with WOCBP partners to prevent potential fetal exposure

Note: Other protocol defined Inclusion/Exclusion Criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05394116


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Locations
Layout table for location information
Japan
Nagoya University Hospital Recruiting
Nagoya, Aichi, Japan, 466-8560
United Kingdom
Royal National Orthropaedic Hospital NHS Trust Recruiting
Middlesex, Greater London, United Kingdom, HA7 4LP
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT05394116    
Other Study ID Numbers: R2477-FOP-2175
2022-000880-40 ( EudraCT Number )
First Posted: May 27, 2022    Key Record Dates
Last Update Posted: January 18, 2023
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy
Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Heterotopic Ossification (HO) Lesions
Type I activin A receptor (ACVR1)
Optima
LUMINA-1
Flare-Ups
Additional relevant MeSH terms:
Layout table for MeSH terms
Myositis Ossificans
Myositis
Muscular Diseases
Musculoskeletal Diseases